CNS Pharmaceuticals, Inc. (CNSP)

NASDAQ: CNSP · IEX Real-Time Price · USD
0.284
-0.006 (-2.00%)
May 16, 2022 4:00 PM EDT - Market closed
Market Cap11.37M
Revenue (ttm)n/a
Net Income (ttm)-13.21M
Shares Out40.03M
EPS (ttm)-0.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume506,739
Open0.290
Previous Close0.290
Day's Range0.270 - 0.299
52-Week Range0.245 - 2.680
Beta2.11
AnalystsBuy
Price Target5.44 (+1,815.5%)
Earnings DateMay 13, 2022

About CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceu...

IndustryPharmaceuticals
IPO DateNov 8, 2019
Employees3
Stock ExchangeNASDAQ
Ticker SymbolCNSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CNSP stock is "Buy." The 12-month stock price forecast is 5.44, which is an increase of 1,815.49% from the latest price.

Price Target
$5.44
(1,815.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Recent approvals of potentially pivotal Berubicin Study into Switzerland, France, and Spain expected to significantly drive patient enrollment Opportunities for Berubicin to be used in additional oncolo...

17 hours ago - PRNewsWire

CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal ...

Continued advancement of global patient enrollment with Switzerland, France, and Spain approvals received for pivotal study of Berubicin HOUSTON , April 28, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc...

2 weeks ago - PRNewsWire

JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ:...

- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and ...

Other symbols:AEZSAREC
1 month ago - Accesswire

CNS Pharmaceuticals to Participate in the Virtual Investor Glioblastoma Multiforme (GBM) Spotlight Event

Live video webcast with moderated fireside chat with members from the CNS Pharmaceuticals management team and featuring Key Opinion Leader, Samuel A. Goldlust, MD, on Thursday, April 14th at 11:30 AM ET...

1 month ago - PRNewsWire

CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal St...

Company continues to drive global patient enrollment in pivotal study of Berubicin HOUSTON , April 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmac...

1 month ago - PRNewsWire

Best Penny Stocks For April 2022? 4 Under $1 To Watch Now

Penny stocks under $1 to watch in April 2022 The post Best Penny Stocks For April 2022? 4 Under $1 To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ADTXGLGNXTP
1 month ago - PennyStocks

CNS Pharmaceuticals Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubi...

Company previously received approval from swissethics, the umbrella organization of the cantonal Ethics Committees (EC) in Switzerland for the study Execution of global patient enrollment continues to p...

1 month ago - PRNewsWire

CNS Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M...

Live webcast fireside chat on Wednesday, March 30 th at 2:30 PM ET HOUSTON , March 23, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company...

1 month ago - PRNewsWire

CNS Pharmaceuticals Reiterates Operational Progress and Addresses Recent Share Price Activity in Video to Shareholders

HOUSTON, March 9, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc.  (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an...

2 months ago - PRNewsWire

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update

HOUSTON, March 3, 2022 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and...

2 months ago - PRNewsWire

Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

CNS Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

HOUSTON, Jan. 20, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

3 months ago - PRNewsWire

CNS Pharmaceuticals Announces Closing of $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, Jan. 10, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and ...

4 months ago - PRNewsWire

CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference

HOUSTON, Jan. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

4 months ago - PRNewsWire

CNS Pharmaceuticals Announces $11.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

HOUSTON, Jan. 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

4 months ago - PRNewsWire

These Penny Stocks Exploded Today, Here's Why

Check these penny stocks out today following big moves The post These Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:DNNLODE
4 months ago - PennyStocks

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Other symbols:APTOCELUCYADSPRB
4 months ago - Zacks Investment Research

Bears are Losing Control Over CNS Pharmaceuticals, Inc. (CNSP), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for CNS Pharmaceuticals, Inc. (CNSP), indicating that the stock has found support. This, combined with an upward trend in earnings ...

4 months ago - Zacks Investment Research

CNS Pharmaceuticals Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubici...

HOUSTON, Dec. 2, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and m...

5 months ago - PRNewsWire

CNS Pharmaceuticals to Present at the Virtual Investor Roundtable Event

HOUSTON, Nov. 16, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and...

6 months ago - PRNewsWire

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical...

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary an...

7 months ago - GlobeNewsWire

CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the...

HOUSTON, Sept. 30, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and...

7 months ago - PRNewsWire

CNS Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Outlook

HOUSTON, Aug. 13, 2021 /PRNewswire/ --  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and...

9 months ago - PRNewsWire

Best Penny Stocks to Buy Right Now? 3 For Your Your July 2021 List

These penny stocks pushed up in recent trading; are they worth watching? The post Best Penny Stocks to Buy Right Now?

Other symbols:TBLT
10 months ago - PennyStocks

WPD Pharmaceuticals' Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Gliobl...

VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce th...

10 months ago - GlobeNewsWire